Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Economic Evaluation of Traditional Treatments for Localized Prostate Cancer, A 10-Year Cohort Study

  • Zamora, Víctor|||0000-0003-2061-0052
  • Bosch, Guillermo
  • Becerra, Virginia|||0000-0002-8811-3899
  • Garin, Olatz|||0000-0001-6193-0779
  • Ávila, Mónica|||0000-0001-9583-5104
  • Gutiérrez Miguélez, Cristina|||0000-0002-6944-772X
  • Suárez, José Francisco|||0000-0001-6427-4391
  • Goñi, Alai|||0000-0002-6365-9617
  • Macías Hernández, Víctor|||0000-0003-2904-5715
  • Mariño, Alfonso|||0000-0002-6720-3916
  • Hervás Morón, Asunción|||0000-0002-7439-1820
  • Herruzo, I.
  • Cabrera, Patricia|||0000-0001-6050-7354
  • Ponce de León Roca, Javier|||0000-0003-0250-2533
  • Sancho-Pardo, Gemma|||0000-0003-2266-6172
  • Pont, À.
  • Rubio-Valera, M.
  • Alonso, Jordi|||0000-0001-8627-9636
  • Cots Reguant, Francesc|||0000-0003-0238-8902
  • Guedea, Ferran|||0000-0001-8798-8696
  • Castells-Esteve, Manel|||0000-0003-2370-2008
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Objectives: To perform a cost-effectiveness analysis based on primary data from a cohort of patients with localized prostate cancer followed throughout 10 years, comparing radical prostatectomy, brachytherapy, and external beam radiotherapy (EBRT) and applying disease-specific utilities, from a national health system's perspective. Materials and Methods: Patients diagnosed with localized prostate cancer were consecutively recruited in 2003-2005 from 10 Spanish hospitals (n = 674) (ClinicalTrials.gov number: NCT01492751). The expanded prostate cancer index composite (EPIC) and short-form 36 (SF-36) questionnaires were administered through telephone interviews before treatment and annually during follow-up. The outcome measures to evaluate the incremental cost-effectiveness ratio between treatments (ICER) were quality-adjusted life-years (QALYs), calculated by the patient-oriented prostate utility scale (PORPUS) utility index, obtained with a mapping from the EPIC and the SF-36, and survival data. Ten-year medical activities were used to derive costs. Both unweighted and propensity score-weighted analyses were performed. Results: The weighted mean of 10-year QALYs was the highest for radical prostatectomy (8.53), followed by brachytherapy (8.49) and external radiotherapy (8.20), but the difference was only statistically significant with the latter. Costs were significantly higher for brachytherapy (€21,348) than radical prostatectomy (€12,281) and EBRT (€7,560). Compared to EBRT, the weighted ICER for radical prostatectomy was €14,169/QALY gained and €48,417/QALY for brachytherapy. Conclusion: Our findings support that radical prostatectomy was the most cost-effective alternative, but the differences in effectiveness among the three treatments were small. The incremental cost of radical prostatectomy and brachytherapy compared to EBRT, however, does not justify restricting these alternatives. Trial Registration: ClinicalTrials.gov identifier: NCT01492751.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Economic evaluation of treatments for patients with localized prostate cancer in Europe, a systematic review

  • Becerra, Virginia|||0000-0002-8811-3899
  • Ávila, Mónica|||0000-0001-9583-5104
  • Jimenez, Jorge
  • Cortes Sanabria, Laura|||0000-0002-2828-3896
  • Pardo Cladellas, Yolanda|||0000-0003-4982-5495
  • Garin, Olatz|||0000-0001-6193-0779
  • Pont, Angels|||0000-0002-0602-552X
  • Alonso, Jordi|||0000-0001-8627-9636
  • Cots Reguant, Francesc|||0000-0003-0238-8902
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Background: Our objective was to assess the efficiency of treatments in patients with localized prostate cancer, by synthesizing available evidence from European economic evaluations through systematic review. Methods: Articles published 2000-2015 were searched in MEDLINE, EMBASE and NHS EED (Prospero protocol CRD42015022063). Two authors independently selected studies for inclusion and extracted the data. A third reviewer resolved discrepancies. We included European economic evaluations or cost comparison studies, of any modality of surgery or radiotherapy treatments, regardless the comparator/s. Drummond's Checklist was used for quality assessment. Results: After reviewing 8,789 titles, 13 European eligible studies were included: eight cost-utility, two cost-effectiveness, one cost-minimization, and two cost-comparison analyses. Of them, five compared interventions with expectant management, four contrasted robotic with non robotic-assisted surgery, three assessed new modalities of radiotherapy, and three compared radical prostatectomy with brachytherapy. All but two studies scored ≥8 in the quality checklist. Considering scenario and comparator, three interventions were qualified as dominant strategies (active surveillance, robotic-assisted surgery and IMRT), and six were cost-effective (radical prostatectomy, robotic-assisted surgery, IMRT, proton therapy, brachytherapy, and 3DCRT). However, QALY gains in most of them were small. For interventions considered as dominant strategies, QALY gain was 0.013 for active surveillance over radical prostatectomy; and 0.007 for robotic-assisted over non-robotic techniques. The highest QALY gains were 0.57-0.86 for radical prostatectomy vs watchful waiting, and 0.72 for brachytherapy vs conventional radiotherapy. Conclusions: Currently, relevant treatment alternatives for localized prostate cancer are scarcely evaluated in Europe. Very limited available evidence supports the cost-effectiveness of radical prostatectomy over watchful waiting, brachytherapy over radical prostatectomy, and new treatment modalities over traditional procedures. Relevant disparities were detected among studies, mainly based on effectiveness. These apparently contradictory results may be reflecting the difficulty of interpreting small differences between treatments regarding QALY gains.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparación de costes de tres tratamientos del cáncer de próstata localizado en España, prostatectomía radical, braquiterapia prostática y radioterapia conformacional externa 3D, Cost comparison of three treatments for localized prostate cancer in Spain

  • Becerra, Virginia|||0000-0002-8811-3899
  • Cots Reguant, Francesc|||0000-0003-0238-8902
  • Guedea, Ferran|||0000-0001-8798-8696
  • Pera, Joan
  • Boladeras, Ana
  • Aguiló Coll, Ferran
  • Suárez, José Francisco|||0000-0001-6427-4391
  • Gallo, Pedro
  • Murgui, Lluis
  • Pont, Angels|||0000-0002-0602-552X
  • Cunillera, O.|||0000-0003-2891-099X
  • Pardo Cladellas, Yolanda|||0000-0003-4982-5495
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Objetivo: comparar los costes de los tratamientos más establecidos para el cáncer de próstata localizado según grupos de riesgo, edad y comorbilidad, desde la perspectiva del proveedor asistencial. Métodos: comparación de costes en pacientes reclutados consecutivamente entre 2003 y 2005 en una unidad funcional de tratamiento del cáncer de próstata. La utilización de servicios hasta 6 meses después del inicio del tratamiento se obtuvo de las bases de datos hospitalarias, y los costes directos se estimaron mediante cálculo microcoste. La información sobre las características clínicas de los pacientes y los tratamientos recogió prospectivamente. Los costes se compararon mediante tests no paramétricos de comparación de medianas (Kruskall-Wallis) y un modelo semilogarítmico de regresión múltiple. Resultados: la diferencia de costes fue estadísticamente significativa: medianas de 3229.10D, 5369.00Dy 6265.60D para los pacientes tratados con radioterapia conformacional externa 3D, braquiterapia, y prostatectomía radical retro pública, respectivamente (p <0,001). En el análisis multivariado (R2 ajustada=0,8), los costes medios de la braquiterapia y de la radioterapia externa fueron significativamente menores que los de la prostatectomía (coeficiente -0,212 y -0,729, respectivamente). Conclusiones: la prostatectomía radical resultó ser la opción terapéutica de mayor coste. En general, los costes estimados en nuestro estudio son inferiores a los publicados en otros ámbitos. La opción terapéutica explica gran parte de los costes, y tanto la comorbilidad como el grupo de riesgo no mostraron efecto independiente del tratamiento sobre los costes totales., Objective: To compare the initial costs of the three most established treatments for clinically localized prostate cancer according to risk, age and comorbidity groups, from the healthcare provider's perspective. Methods: We carried out a cost comparison study in a sample of patients consecutively recruited between 2003 and 2005 from a functional unit for prostate cancer treatment in Catalonia (Spain). The use of services up to 6 months after the treatment start date was obtained from hospital databases and direct costs were estimated by micro-cost calculation. Information on the clinical characteristics of patients and treatments was collected prospectively. Costs were compared by using nonparametric tests comparing medians (Kruskall-Wallis) and a semi-logarithmic multiple regression model. Results: Among the 398 patients included, the cost difference among treatments was statistically significant: medians were €3,229.10, €5,369.00 and €6,265.60, respectively, for the groups of patients treated with external 3D conformal radiotherapy, brachytherapy and radical retropublic prostatectomy, (p<0.001). In the multivariate analysis (adjusted R=0.8), the average costs of brachytherapy and external radiotherapy were significantly lower than that of prostatectomy (coefficient -0.212 and -0.729, respectively). Conclusions: Radical prostatectomy proved to be the most expensive treatment option. Overall, the estimated costs in our study were lower than those published elsewhere. Most of the costs were explained by the therapeutic option and neither comorbidity nor risk groups showed an effect on total costs independent of treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparative Effectiveness Research in Localized Prostate Cancer, A 10-Year Follow-up Cohort Study

  • Garin, Olatz|||0000-0001-6193-0779
  • Suárez, J.F.
  • Guedea, Ferran|||0000-0001-8798-8696
  • Pont, À.
  • Pardo Cladellas, Yolanda|||0000-0003-4982-5495
  • Goñi, Alai|||0000-0002-6365-9617
  • Mariño, Alfonso|||0000-0002-6720-3916
  • Hervás Morón, Asunción|||0000-0002-7439-1820
  • Herruzo, I.
  • Cabrera, Patricia|||0000-0001-6050-7354
  • Sancho-Pardo, Gemma|||0000-0003-2266-6172
  • Ponce de León Roca, Javier|||0000-0003-0250-2533
  • Macías Hernández, Víctor|||0000-0003-2904-5715
  • Gutierrez, Cristina
  • Castells-Esteve, Manel|||0000-0003-2370-2008
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Purpose: Long-term comparative effectiveness research on localized prostate cancer treatments is scarce, and evidence is lacking especially for brachytherapy. The aim of this study was to assess the long-term impact of the side effects of radical prostatectomy, brachytherapy, and external radiation therapy on patients with localized prostate cancer at 10 years, using propensity score analyses. Methods and Materials: This was a prospective observational study of a cohort of men who received a diagnosis of clinically localized prostate cancer (clinical stage T1 or T2, low and intermediate risk group) and were treated with radical prostatectomy (n = 139), brachytherapy (n = 317), or external radiation therapy (n = 194). Treatment decisions were jointly made by patients and physicians. Patient-reported outcome (PRO) evaluation included the Expanded Prostate Cancer Index Composite and Short Form-36, administered centrally by telephone interviews before and annually after treatment. The Expanded Prostate Cancer Index Composite covers urinary, bowel, sexual, and hormonal domains. To assess PRO changes over time, while accounting for correlation among repeated measures, generalized estimating equation models adjusted by propensity scores were constructed. Results: The PRO completion rate at 10 years was 85.8%. Generalized estimating equation models showed that the pattern of radical prostatectomy side effects, with substantial urinary incontinence and sexual dysfunction, remained until 10 years after treatment (standard deviation [SD], -1.1 and -1.3, respectively). Brachytherapy produced late deterioration in urinary continence (SD, -0.4) and sexual function (SD, -0.9) that appeared midterm, but the differences from radical prostatectomy remained statistically significant at 10 years (P <.001 after adjusting by propensity score). External radiation therapy showed similar results to brachytherapy, but with bowel bother (SD, -0.3). Conclusions: Although late deterioration in radiation therapy groups attenuated differences from radical prostatectomy, relevant PRO differences still remained after 10 years. Our findings support that brachytherapy is the treatment option that causes the least impact on PROs; it is therefore an alternative to be considered when making evidence-based decisions on localized prostate cancer treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer, a 10-year follow-up cohort study

  • Suárez, José Francisco|||0000-0001-6427-4391
  • Zamora, Víctor|||0000-0003-2061-0052
  • Garin, Olatz|||0000-0001-6193-0779
  • Gutiérrez, Cristina|||0000-0003-2626-1957
  • Pont, Angels|||0000-0002-0602-552X
  • Pardo Cladellas, Yolanda|||0000-0003-4982-5495
  • Goñi, Alai|||0000-0002-6365-9617
  • Mariño, Alfonso|||0000-0002-6720-3916
  • Hervás, Asunción
  • Herruzo, Ismael
  • Cabrera, Patricia|||0000-0001-6050-7354
  • Sancho-Pardo, Gemma|||0000-0003-2266-6172
  • Ponce de León Roca, Javier|||0000-0003-0250-2533
  • Macías Hernández, Víctor|||0000-0003-2904-5715
  • Guedea, Ferran|||0000-0001-8798-8696
  • Vigués, Francesc|||0000-0003-3717-6301
  • Castells-Esteve, Manel|||0000-0003-2370-2008
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
To compare the effectiveness at ten years of follow-up of radical prostatectomy, brachytherapy and external radiotherapy, in terms of overall survival, prostate cancer-specific mortality and biochemical recurrence. Cohort of men diagnosed with localized prostate cancer (T1/T2 and low/intermediate risk) from ten Spanish hospitals, followed for 10 years. The treatment selection was decided jointly by patients and physicians. Of 704 participants, 192 were treated with open radical retropubic prostatectomy, 317 with 125 I brachytherapy alone, and 195 with 3D external beam radiation. We evaluated overall survival, prostate cancer-specific mortality, and biochemical recurrence. Kaplan-Meier estimators were plotted, and Cox proportional-hazards regression models were constructed to estimate hazard ratios (HR), adjusted by propensity scores. Of the 704 participants, 542 patients were alive ten years after treatment, and a total of 13 patients have been lost during follow-up. After adjusting by propensity score and Gleason score, brachytherapy and external radiotherapy were not associated with decreased 10-year overall survival (aHR = 1.36, p = 0.292 and aHR = 1.44, p = 0.222), but presented higher biochemical recurrence (aHR = 1.93, p = 0.004 and aHR = 2.56, p < 0.001) than radical prostatectomy at ten years of follow-up. Higher prostate cancer-specific mortality was also observed in external radiotherapy (aHR = 9.37, p = 0.015). Novel long-term results are provided on the effectiveness of brachytherapy to control localized prostate cancer ten years after treatment, compared to radical prostatectomy and external radiotherapy, presenting high overall survival, similarly to radical prostatectomy, but higher risk of biochemical progression. These findings provide valuable information to facilitate shared clinical decision-making. Study identifier at ClinicalTrials.gov : NCT01492751.